← All indications
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
Subtype terms (1)
More specific conditions that are subtypes of Graft vs Host Disease in the MeSH hierarchy.
- Bronchiolitis Obliterans Syndrome
1 drug approved
Drugs by status
Approved for this indication (5)
Phase 4 trials (22)
Phase 3 trials (50)
- brimonidine
- decitabine
- methylprednisolone
- acetylcysteine
- urea
- begelomab
- busulfan
- carbon dioxide
- efprezimod alfa
- clobetasol
- progesterone
- alpha-1 antitrypsin
- etanercept
- imatinib
- hydroxychloroquine
- bone marrow derived mesenchymal stem cells
- aldesleukin
- albumin (Human)
- beclomethasone
- alefacept
- itacitinib
- leucovorin
- methoxsalen
- myeloma immunoglobulin idiotype vaccine-klh
- allogeneic stem cells
- sitagliptin
- semustine
- everolimus
- alemtuzumab
- nicotinamide
- +20 more
Phase 2 trials (148)
- montelukast
- cladribine
- thalidomide
- azacitidine
- saracatinib
- fluticasone
- ibritumomab tiuxetan
- azd9668
- acalabrutinib
- cmv-specific t-cells
- anlotinib
- allogeneic natural killer cells
- aminolevulinic acid
- maraviroc
- autologous blood
- autologous expanded mesenchymal stem cells oti-010
- sorafenib
- bms-986004
- brentuximab vedotin
- irinotecan
- carfilzomib
- lenalidomide
- clazakizumab
- clofarabine
- diphenhydramine
- defibrotide
- denileukin diftitox
- valproic acid
- dornase alfa
- echinacea
- +118 more
Phase 1 trials (51)
- fluorothymidine
- allopurinol
- 7-hydroxystaurosporine
- alvespimycin
- activated marrow infiltrating lymphocytes
- cholestyramine
- entolimod
- photochlor
- epidermal growth factor
- hydroxyurea
- meperidine
- lifitegrast
- milatuzumab
- motolimod
- neihulizumab
- vitamin c
- pirfenidone
- platelet poor plasma
- methylene blue
- sunitinib
- rasburicase
- Ivarmacitinib
- siplizumab
- sonidegib
- teduglutide
- fluconazole
- uttr1147a
- amniotic epithelial cells
- autologous fecal microbiota
- cd4+cd25+ regulatory t cells
- +21 more
Organizations
Organization Involved with Phase 4 Indications (19)
- Astellas
- Pharmacyclics
- Pfizer
- Wyeth
- Harvard University
- Guangxi Medical University
- Hacettepe University
- Katholieke Universiteit Leuven
- Nanjing University
- Radboud University
- University of Iowa
- University of Maryland
- Fujian Medical University
- Xiamen University
- Southern Medical University
- Sun Yat-Sen University
- Janssen Pharmaceutica NV
- Sungkyunkwan University
- People's Liberation Army of China
Organization Involved with Phase 3 Indications (70)
- CSL Behring
- Incyte
- Abgenix
- Adienne SA
- Millennium Pharmaceuticals
- Osiris Therapeutics
- Novartis
- Baxalta
- Chimeric Therapies
- Kamada, Ltd.
- Mallinckrodt
- OncoImmune, Inc.
- Rafa Laboratories
- Sangstat Medical Corporation
- Enteron Pharmaceuticals
- Neovii Biotech
- Soligenix
- National Institutes of Health (NIH)
- Center for International Blood and Marrow Transplant Research
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- Dr. Falk Pharma GmbH
- Huazhong University of Science and Technology
- Medical University of Graz
- Centre National de Greffe de Moelle Osseuse
- Cornell University
- European Group for Blood and Marrow Transplantation
- Duke University
- +40 more
Organization Involved with Phase 2 Indications (177)
- Swedish Orphan Biovitrum
- Actelion
- Jazz Pharmaceuticals
- Kadmon
- Facet Biotech
- Takeda
- Celgene
- Bristol-Myers Squibb
- Amgen
- Fresenius
- Roche
- Gilead Sciences
- AstraZeneca
- Genentech
- Genzyme
- Sanofi
- Biogen
- PDL BioPharma
- Alexion
- Bayer
- Bellicum Pharmaceuticals
- Biocon Limited
- CABYC
- CTI BioPharma
- Cellect Biotechnology
- Crolll Gmbh
- Fate Therapeutics
- GliaCure, Inc.
- Henogen
- Innovent Biologics (Suzhou) Co. Ltd.
- +147 more
Organization Involved with Phase 1 Indications (24)
- AltruBio
- Seattle Genetics
- Immunomedics
- MedImmune
- CellSight Technologies, Inc.
- GlaxoSmithKline
- Parexel
- Syndax Pharmaceuticals
- Cynata Therapeutics Limited
- Medical Research Council
- Azienda Ospedaliera San Gerardo di Monza
- Dartmouth University
- Gruppo Italiano Trapianto di Midollo Osseo
- San Gerardo Hospital
- University of Kansas
- Marche Polytechnic University
- Columbia University
- University of California, Davis
- University of Tuebingen
- Miltenyi Biotec, Inc.
- CURE Foundation
- BioIncept LLC
- American Cancer Society, Inc.
- Alpine Immune Sciences
Organization Involved with Other Experimental Indications (11)
- Bausch & Lomb
- myTomorrows
- National Center for Research Resources (NCRR)
- University of Florida
- University of California, San Diego
- University of Ulsan
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- The University of Hong Kong
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
- Government of Hong Kong
- The Hong Kong Blood Cancer Foundation